Welcome

Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and
others concerned about HIV/AIDS. Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the
conversation yourself by registering on the left side of this page.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive
and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a
username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own
physician.

All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators
of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please
provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are
true and correct to their knowledge.

GeoVax Labs, Inc., an Atlanta-based biotechnology company, presented additional results on Wednesday from a Phase IIa trial evaluating the safety and immunogenicity of the company’s first generation preventive HIV vaccine.

The company presented the results from HVTN 205, a multi-center, randomized Phase IIa trial, at the 2013 AIDS Vaccine Meeting in Barcelona. The trial found that at six months following vaccination, patient antibody levels dropped less than three-fold, indicating significant durability of the antibody response.

The study tested the prime-boost vaccine regimen of GeoVax’s DNA vaccine and modified vaccinia Ankara vaccine in healthy adults uninfected by HIV. Six months after vaccination, antibody response titers in the MVA vaccine arm only dropped from 100 percent to 84 percent. The study also showed that the antibody responses after vaccination had high affinity binding, a characteristic associated with HIV infection prevention in preclinical models.

“We are very pleased with the durability of our antibody responses,” Harriet Robinson, the chief scientific officer at GeoVax, said. “We are also encouraged that our vaccine is eliciting tightly binding Ab in humans. The key to a successful preventive vaccine is the antibody response, which needs to be both sustained and capable of high affinity binding.”

The study was conducted by the HIV Vaccine Trials Network, with support from the National Institute of Allergy and Infectious Disease. The HVTN is also conducting a Phase I trial of GeoVax’s second-generation DNA/MVA vaccine.